WINNIPEG, Manitoba--(BUSINESS WIRE)--#Cubresa--Case Western Reserve University (CWRU) has selected Cubresa’s Preclinical NuPET™ Insert System to add to their suite of imaging tools. The NuPET 66 will support research in a wide range of application ar
Live Call/Webcast on Wednesday, February 23, 2022 at 5 pm ET TORONTO & DALLAS--(BUSINESS WIRE)--$PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven
QUEBEC CITY--(BUSINESS WIRE)--#biotech--Saguaro Technologies Inc. announces the closing of a $1.1M start-up financing led by a seasoned biotech investor and including non-dilutive grant funding. “We are pleased to close our first financing and to welco
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chief Ex
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Oligon™ Inc., an emerging biotechnology company developing a novel class of multimodal RNA therapeutics for the treatment of cancer and other complex diseases, announced today that Dr. Spyro Mousses, Chief Executive O
TORONTO--(BUSINESS WIRE)--Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, plans to expand the presence of its Novasight Hybrid System in the U.S. market in 2022 under the guidance o
CHATHAM, Ontario--(BUSINESS WIRE)--#alternativeassets--AGinvest Farmland Properties Canada Inc ("AGinvest") is pleased to announce the 2021 farmland investment performance results. In addition to very strong annual investment returns to report, AGinvest a
Company to commercialize and create single-cell multi-omics products SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a company dedicated to providing scalable single-cell sequencing solutions, today announced $41.5M in Series B funding co-led by Marshall Wa
Following the positive outcome of a meeting with the FDA, a first patient was recruited in the Phase 3 expansion of the RESOLUTION study with LAU-7b in hospitalized moderate-to-severe COVID-19 patients Results from the RESOLUTION Phase 2 pilot portion s
VANCOUVER, British Columbia--(BUSINESS WIRE)--Eat Well Investment Group Inc. (CSE: EWG) (US:EWGFF) (FSE: 6BC0) (“Eat Well” or the “Company”) is pleased to announce that it has closed a strategic investment (the “Strategic Investment”) from Nur
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.